PCM
SVA

Prelude Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Prelude Capital Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,000
Closed -$86K – 2162
2018
Q1 		$86K Sell
10,000
-3,200
-24% -$26.4K 0.01% 917
2017
Q4 		$104K Hold
13,200
– – 0.01% 779
2017
Q3 		$93K Buy
13,200
+4,400
+50% +$30K 0.01% 905
2017
Q2 		$59K Buy
+8,800
New +$48.2K 0.01% 957
2014
Q3 		– Sell
-5,000
Closed -$28K – 2459
2014
Q2 		$28K Sell
5,000
-12,700
-72% -$77.1K ﹤0.01% 1656
2014
Q1 		$127K Buy
+17,700
New +$117K 0.02% 926

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Prelude Capital Management's SVA Position: Q2 2018 in Review

Prelude Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2018, closing a stake of 10,000 shares — an estimated $86K sold.

Prelude Capital Management first reported a position in SVA in Q1 2014 and held it in 6 quarters. The position peaked at $127K in Q1 2014. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2018.

  • Prelude Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2018 after selling out during the quarter.
  • Prelude Capital Management sold 10,000 Sinovac Biotech, Ltd shares in Q2 2018, an estimated $86K.
  • Prelude Capital Management first reported a position in Sinovac Biotech, Ltd in Q1 2014 and held it in 6 quarters.
  • Prelude Capital Management's Sinovac Biotech, Ltd position peaked at $127K in Q1 2014.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.